Key facts, as of
As of November 2, 2026, Abbott Laboratories (ABT) trades at $110.11, down 10.9% over the past year. Its 52-week range runs from $81.97 to $132.03; the price is 16.6% below that high. It is 22.8% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +226.6%, against +316.3% for the S&P 500 (SPY). It sits 8.3% above its 200-day average of $101.63, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 24.4% annualized, which we rate medium risk. It has a trailing P/E of 40.9 and a dividend yield of 2.37%.
Cite: Portfolio Terminal, "Abbott Laboratories (ABT) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/abt
Where it trades today
trading 56% of the way up its 52-week range
How the price has moved
How far it is from its record
Abbott Laboratories (ABT) is 22.8% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +226.6%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- ABT closes above its 50-day average ($104.21), and the 50-day sits above the 200-day ($101.63): on both averages the chart reads as an uptrend.
- At $110.11, ABT is 16.6% below its 1-year high of $132.03, set on November 18, 2025, and 34.3% above its 1-year low of $81.97 (May 11, 2026).
- Over the past month ABT rose 12.9%, from $97.50 to $110.11.
- ABT trades at 40.9x its last twelve months of earnings and 18.5x the next twelve months' estimate, so analysts expect earnings 120.7% higher.
- Its P/E is 25.7% above the 32.6x median of the 3 other medical devices companies we track (SYK, BSX, EW).
- ABT's 30-day volatility, 24.4% a year, works out to a typical daily move of about 1.5%.
- Yahoo Finance puts its beta at 0.54: over five years of monthly returns, ABT moved about 0.54% for each 1% move of the S&P 500.
- The last session traded 0.5x ABT's average daily volume of the 30 sessions before it.
What would change the read
- A close under the 50-day average, $104.21 (−5.4% from the last close), would turn the read to a pullback; under the 200-day, $101.63 (−7.7%), the longer rise is in question.
- A close above $132.03 (+19.9%) would be a new 1-year high; below $81.97 (−25.6%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for ABT, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for ABT by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for ABT. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What Abbott Laboratories does
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective…
What analysts expect
ABT carries a buy consensus from 26 analysts, with an average price target of $118.52 versus $110.11 today (+7.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ABT generated $48.23B in trailing revenue (14.5% year over year), with a 9.7% net margin, against $27.12B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $44.33B | $25.01B | $8.05B | $6.52B | $3.76 | $7.39B |
| 2024 | $41.95B | $23.24B | $6.83B | $13.40B | $7.74 | $6.35B |
| 2023 | $40.11B | $22.13B | $6.48B | $5.72B | $3.30 | $5.06B |
| 2022 | $43.65B | $24.51B | $8.36B | $6.93B | $3.99 | $7.80B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ABT is in 18 of the 54 ETFs we track. It weighs most in SCHD: 3.87% of the fund, holding #10 of 100.
How its figures compare with those peers
Companies in the same industry
ABT beside the other companies Yahoo Finance files under medical devices among the assets we track (SYK, BSX, EW, largest first).
ABTyou are here$110.11$190.53B
SYKStryker Corporation$305.71$116.38B
BSXBoston Scientific$44.12$63.94B
EWEdwards Lifesciences$92.44$53.28BWhat the chart is saying
In an uptrend, pressing toward $117.08 resistance.
uptrend- Price is 5.7% above its 50-day average and 8.3% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-16 (a “golden cross”).
- RSI at 67 is neither stretched nor washed out.
- The nearest ceiling is $117.08 (+6.3%), the nearest floor $104.55 (-5.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is ABT valued right now?
Abbott Laboratories trades at 40.9 times its last twelve months of earnings and 18.5 times the next twelve months' estimate (Yahoo Finance, November 2, 2026). On the chart: in an uptrend, pressing toward $117.08 resistance. Price is 5.7% above its 50-day average and 8.3% above its 200-day.
What is the risk level of ABT?
Based on 30-day volatility of 24.4%, ABT has MEDIUM risk. Its beta of 0.54 means it has swung less than the S&P 500 over the last five years.
Does ABT pay dividends?
Yes, Abbott Laboratories has a dividend yield of 2.37%.
How far is ABT from its all-time high?
Abbott Laboratories is 22.8% below its all-time high of $142.60, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +226.6%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold ABT?
18 of the 54 popular ETFs we track hold Abbott Laboratories. The largest weights: SCHD (3.87%), XLV (2.83%), VIG (0.76%), VYM (0.73%) and VTV (0.65%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is ABT?
0.26%, as of September 30, 2026: ABT is holding #65 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.60 in Abbott Laboratories.
What is the analyst price target for ABT?
The average analyst price target for Abbott Laboratories (ABT) is $118.52 based on 26 analyst estimates, about 7.6% above the current price of $110.11. The published range runs from $100.00 to $130.00.
How much revenue does ABT generate?
Abbott Laboratories reported $48.23B in trailing twelve-month revenue. Revenue growth is running at 14.5% year over year. Net margin sits at 9.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ABT with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.